scholarly journals Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?

2020 ◽  
Vol 40 (10) ◽  
pp. 897-899 ◽  
Author(s):  
Bruno Charpiat ◽  
Nathalie Bleyzac ◽  
Michel Tod
Keyword(s):  
Risk Factors ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Viral Infections

Risk of Clostridium difficile-Associated Disease Among Patients Receiving Proton-Pump Inhibitors in a Quebec Medical Intensive Care Unit

2007 ◽  
Vol 28 (11) ◽  
pp. 1305-1307 ◽  
Author(s):  
Mathieu Beaulieu ◽  
David Williamson ◽  
Gilbert Pichette ◽  
Jean Lachaine
Keyword(s):  
Risk Factors ◽  
Intensive Care Unit ◽  
Intensive Care ◽  
Clostridium Difficile ◽  
Gastric Acid ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Medical Intensive Care Unit ◽  
Antibiotic Use ◽  
Medical Intensive Care

Our study was conducted to determine whether use of gastric acid-suppressive agents increased the risk of Clostridium difficile-associated disease (CDAD) in a medical intensive care unit of one of the first hospitals to be threatened by the current CDAD epidemic in Quebec, Canada. Our findings suggest that efforts to determine risk factors for CDAD should focus on other areas, such as older age and antibiotic use.

Mo1083 Risk Factors for Relapse of Gastroesophageal Reflux Disease (GERD) in Primary Care Patients Previously Succeeded With Proton Pump Inhibitors Treatment

2012 ◽  
Vol 142 (5) ◽  
pp. S-590-S-591
Author(s):  
Magda Sofia Pacio-Quiterio ◽  
Jose Emilio G Rodriguez-Aguilar ◽  
Alvaro Montiel-Jarquin ◽  
Juan C. Lopez-Alvarenga ◽  
Sergio R. Sobrino-Cossio ◽  
...  
Keyword(s):  
Risk Factors ◽  
Primary Care ◽  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Reflux Disease ◽  
Primary Care Patients

scholarly journals Risk factors for Salmonella Enteritidis and Typhimurium (DT104 and non-DT104) infections in The Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in Typhimurium infections

2005 ◽  
Vol 134 (3) ◽  
pp. 617-626 ◽  
Author(s):  
Y. DOORDUYN ◽  
W. E. VAN DEN BRANDHOF ◽  
Y. T. H. P. VAN DUYNHOVEN ◽  
W. J. B. WANNET ◽  
W. VAN PELT
Keyword(s):  
Risk Factors ◽  
The Netherlands ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Salmonella Enteritidis ◽  
Phage Type ◽  
Population Attributable Risk ◽  
Frequency Matching ◽  
Infection Risk Factors ◽  
Control Study

Since 1996 Salmonella Typhimurium DT104 salmonellosis has increased in The Netherlands. This prompted a case-control study of risk factors for salmonellosis to inform transmission routes for this phage type. Cases were laboratory-confirmed patients with a Salmonella infection and controls were selected from population registries by frequency matching for age, sex, degree of urbanization and season. Cases and controls received a questionnaire on risk factors. Of the 1171 cases, 573 (49%) responded: 245 S. Enteritidis and 232 S. Typhimurium cases (both DT104 and non-DT104), of which 58 were DT104. Of the 10250 controls, 3409 (33%) responded. Use of H2 antagonists [odds ratio (OR) 4·4, 95% CI 1·6–12·2] and proton pump inhibitors (OR 4·2, 95% CI 2·2–7·9), consumption of raw eggs (OR 3·1, 95% CI 1·3–7·4) and products containing raw eggs (OR 1·8, 95% CI 1·1–3·0) were associated with endemic S. Enteritidis infection. Risk factors for endemic S. Typhimurium infection were use of proton pump inhibitors (OR 8·3, 95% CI 4·3–15·9), occupational exposure to raw meat (OR 3·0, 95% CI 1·1–7·9), playing in a sandbox (for children aged 4–12 years) (OR 2·4, 95% CI 1·6–3·7), consumption of undercooked meat (OR 2·2, 95% CI 1·1–4·1) and use of antibiotics (OR 1·9, 95% CI 1·0–3·4). Use of proton pump inhibitors (OR 11·2, 95% CI 3·9–31·9) and playing in a sandbox (OR 4·4, 95% CI 1·8–10·7) were the only risk factors for S. Typhimurium DT104 salmonellosis. This study confirms known risk factors for salmonellosis. However, playing in a sandbox was a predominant new risk factor for S. Typhimurium salmonellosis in children [population attributable risk (PAR) 14%], and especially for S. Typhimurium DT104 (PAR 32%).

Proton Pump Inhibitors and Corticosteroids as Synergistic Risk Factors for Candida Esophagitis

2015 ◽  
Vol 110 ◽  
pp. S737-S738
Author(s):  
Nihar Shah ◽  
Yana Cavanagh ◽  
Oleg Shulik ◽  
Pooja Patel ◽  
Vincent DeBari ◽  
...  
Keyword(s):  
Risk Factors ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Candida Esophagitis

Proton Pump Inhibitors and the Prevention of Recurrent GI Bleed in Patients Treated with Clopidogrel

2012 ◽  
Vol 4 ◽  
pp. CMT.S7253
Author(s):  
O.O. Oyetayo ◽  
C.A. Farris ◽  
J. Wahawisan
Keyword(s):  
Risk Factors ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Antiplatelet Agent ◽  
Antiplatelet Agents ◽  
Gi Bleeding ◽  
Gi Tract ◽  
Major Site ◽  
Inflammatory Drugs ◽  
Gi Bleed

Clopidogrel is an antiplatelet agent indicated in the management of atherothrombotic conditions. Bleeding is a predictable adverse event associated with antiplatelet agents. While non-ulcerogenic; a major site of bleeding with clopidogrel is the gastrointestinal (GI) tract. The risk of GI bleeding with clopidogrel monotherapy is generally low; however, it increases with the presence of other risk factors such as aspirin use, advanced age, prior GI bleed, non-steroidal anti-inflammatory drugs, steroids and anticoagulants. In patients with a prior GI bleed, the risk of recurrence is high and strategies to prophylactically mitigate the risk should be implemented. In this review, evidence supporting the use of proton pump inhibitors to reduce the risk of recurrent GI bleed is discussed. Recommendations on an appropriate regimen to diminish the risk are provided.

scholarly journals Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases

2007 ◽  
Vol 136 (9) ◽  
pp. 1225-1234 ◽  
Author(s):  
Y. DOORDUYN ◽  
W. VAN PELT ◽  
C. L. E. SIEZEN ◽  
F. VAN DER HORST ◽  
Y. T. H. P. VAN DUYNHOVEN ◽  
...  
Keyword(s):  
Risk Factors ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Reactive Arthritis ◽  
Buccal Swab ◽  
Nucleotide Polymorphisms ◽  
Host Genetics ◽  
Guillain Barré ◽  
Chronic Sequelae

SUMMARYWe studied the role of host genetics in the susceptibility to severeSalmonellaandCampylobacterinfections and chronic sequelae of these infections. Participants of a previous case-control study were sent a buccal swab kit and a questionnaire about occurrence of chronic sequelae. Single nucleotide polymorphisms (SNPs) in theTLR4(rs4986790),IFNG(rs2430561 and rs1861493),STAT1(rs1914408),IL1B(rs16944),NRAMP(SLC11A1rs2276631),JUN(rs11688) andVDR(rs10735810) genes were determined. In total, 687 controls, 457Campylobactercases and 193Salmonellacases participated. None of the SNPs were associated withCampylobacterorSalmonellainfections. None of the participants developed Guillain–Barré, Miller–Fisher or Reiter's syndrome. Reactive arthritis occurred in 5% and 2% of cases and controls, respectively.Campylobactercases more frequently experienced gastroenteritis episodes than controls.CampylobacterorSalmonellainfection in women, use of proton pump inhibitors and an SNP in theIFNGgene were independent risk factors for reactive arthritis. Another SNP in theIFNGgene and use of proton pump inhibitors were risk factors for recurrent episodes of gastroenteritis. In conclusion, reactive arthritis and recurrent gastroenteritis episodes are common after infection and host genetic factors play a role in susceptibility to these long-term health effects.

scholarly journals Which impact for proton pump inhibitors in SARS-COV-2 pneumonia

2021 ◽  
Author(s):  
Grazia Mazzeo ◽  
Luigi Aronne ◽  
Domenica Francesca Mariniello ◽  
Valentino Allocca ◽  
Maria Ilaria Palma ◽  
...  
Keyword(s):  
Risk Factors ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Randomized Trials ◽  
Severe Pneumonia ◽  
Histamine Receptor ◽  
Underlying Disease ◽  
Disease Course ◽  
Risk Of Mortality ◽  
Stomach Acid

Identification of risk factors for severe outcome of Sars-Cov-2 infection is an important issue in COVID-19 management. Much attention has been focused on comorbidities as well as drugs taken by patients. Usage of proton pump inhibitors (PPIs) appears to potentially influence disease course. These drugs are known to reduce stomach acid and also modulate the immune system. Their use, prior to and during COVID-19 infection, seems to predispose to the development of more severe pneumonia and therefore to a greater risk of mortality. Instead, the use of Histamine receptor 2 antagonists (H2RAs) seems to be associated with a better outcome in patients with COVID-19, in terms of symptoms, risk of intubation and death. As PPIs are essential for treatment of many disorders, usage of these drugs should be balanced considering the benefits and risk ratio, in order to guarantee their correct use for the necessary time. It remains to be clarified whether the detrimental effects, in terms of COVID19 severe outcome, are due to PPIs or to the underlying disease for which they are administered. New controlled-randomized trials are required to better understand their impact in SARS-COV-2 infections. *Vanvitelli/Monaldi COVID Group: Adriano Cristinziano, Carolina Delle Donne, Cecilia Calabrese, Fabio Perrotta, Filippo Scialò, Francesco Lassandro, Gennaro Mazzarella, Giorgio Paoli, Leonardo De Luca, Maria Galdo, Miriam Buonincontro, Roberta Cianci, Rosalba Donizzetti, Stefano Sanduzzi Zamparelli, Tullio Valente, Vito D’Agnano, Vittorio Bisogni

Sign in / Sign up

Export Citation Format

Share Document